• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mergers & Acquisitions

Dexcom quashes talk of Insulet merger, says discussions are not ongoing

May 31, 2022 By Sean Whooley

Dexcom Insulet Omnipod 5 G6

Dexcom (Nasdaq:DXCM) today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD). Last week, reports circulated saying talks over a potential acquisition were ongoing,  with an agreement between the two diabetes technology developers on the horizon in the coming weeks. On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 apiece […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Patient Monitoring, Technology Tagged With: Dexcom, Insulet

Report: Dexcom in talks to acquire Insulet

May 23, 2022 By Sean Whooley

Dexcom Insulet Omnipod 5 G6

Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg said its sources preferred […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Patient Monitoring, Technology Tagged With: Dexcom, Insulet

Medtronic completes Intersect ENT acquisition

May 13, 2022 By Sean Whooley

Medtronic Intersect ENT

Medtronic (NYSE:MDT) announced that it completed its previously announced $1.1 billion acquisition of Intersect ENT (Nasdaq:XENT). Fridley, Minnesota-based Medtronic announced in August 2021 that it would acquire all outstanding shares of the Menlo Park, Calif.-based sinus implant maker for $28.25 per share in an all-cash transaction. As a result of the transaction, Medtronic acquires Intersect ENT’s Propel and Sinuva drug-eluting […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Mergers & Acquisitions, Otolaryngology Ear, Nose & Throat Tagged With: Intersect ENT Inc., Medtronic

Halozyme acquires Antares Pharma for $960M to create drug delivery company

April 13, 2022 By Sean Whooley

Halozyme Antares

Halozyme Therapeutics (Nasdaq:HALO) announced today that it will acquire Antares Pharma (Nasdaq:ATRS) for approximately $960 million. Both companies’ boards of directors approved the transaction, which will see Halozyme acquire Antares for $5.60 per share in cash. According to a news release, the business combination will create a leading drug delivery and specialty product company with […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Antares Pharma, Halozyme Therapeutics

How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD

April 5, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Patient Monitoring, Research & Development, Technology, Wall Street Beat Tagged With: BD, embecta

Fresenius Kabi to acquire Ivenix and its smart infusion system for $240M upfront

March 31, 2022 By Sean Whooley

Fresenius Kabi Ivenix

Fresenius Kabi announced today that it will acquire Ivenix with plans to bring a comprehensive infusion product portfolio to the U.S. The acquisition, which has a purchase price of $240 million upfront, also includes potential milestone payments linked to achievements of commercial and operating targets. According to a news release, the companies expect the acquisition […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: Fresenius, freseniuskabi, Ivenix, mAbxience

Glooko acquires Diabnext and its digital health platform for managing diabetes

March 16, 2022 By Sean Whooley

Glooko XT Diabnext

Glooko announced today that it acquired Diabnext, a developer of a digital health platform for managing diabetes and connecting to healthcare providers. Paris-based Diabnext’s mobile app tracks diabetes data so that physicians can collaborate with their patients to monitor individual patient data and provide remote care. Financial details of the acquisition were not disclosed. Palo […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Patient Monitoring, Technology Tagged With: Diabnext, glooko

Second Sight Medical, Nano Precision Medical merging to create therapeutic implant company

February 8, 2022 By Sean Whooley

Second Sight Medical Nano Precision Medical

Second Sight Medical Products (NSDQ:EYES) and Nano Precision Medical agreed to a merger deal that will focus on drug-device medical implants. The two companies entered into a definitive agreement under which privately held Nano Precision Medical (NPM) will merge with a wholly-owned subsidiary of Second Sight in an all-stock transaction, with NPM the surviving company […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Mergers & Acquisitions, Optical/Ophthalmic, Pharmaceuticals Tagged With: Nano Precision Medical, Second Sight

Novo Nordisk completes acquisition of Dicerna Pharmaceuticals

December 28, 2021 By Sean Whooley

Novo Nordisk Dicerna Pharmaceuticals

Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Dicerna Pharmaceuticals, Novo Nordisk

Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires

December 27, 2021 By Sean Whooley

Novo Nordisk Dicerna Pharmaceuticals

Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired. The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Dicerna Pharmaceuticals, Novo Nordisk

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 17
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS